4-Antibody AG to Relocate to New Labs in Basel
The company’s new location is part of a new facility being opened today by Councillor Christoph Brutschin, Head of the Department for Economic, Social and Environmental Affairs for the Canton Basel-Stadt. The Technology Park Basel is supported by the Canton Basel-Stadt and the federal agency SECO and provides infrastructure for growing ‘high tech’ companies, particularly from the life sciences sector which are looking for fully equipped laboratory facilities. The Technology Park is located next to the ‘Basel Incubator’, managed by the start-up agency EVA and supported by the University of Basel, the Fachochschule Nordwestschweiz, and the Canton Basel-Stadt. The combination of the ‘Basel Incubator’ for emerging companies and growing companies relocating to the Technology Park is expected to create a new, dynamic, ‘high tech‘ life sciences ‘hub’ within Basel. 4-Antibody is the Technology Park’s first tenant.
Dr Ulf Grawunder, 4-Antibody’s CSO, said:
“Being able to upgrade our Basel lab facilities with this move to the Technology Park is another strong indication of the momentum being created by 4-Antibody’s exciting antibody discovery platform. We feel privileged to be the first tenants in this new world-class facility and expect that many other biotech companies in the region will follow in our footsteps. These new Basel lab facilities and our existing labs in Jena are both state of the art”
About 4-Antibody AG
4-Antibody is a biopharmaceutical company with a powerful fully-human antibody drug-discovery technology platform which is generating an emerging pipeline of antibody therapeutics. The proprietary discovery engine is the in vitro Retrocyte Display® technology, a fast and highly efficient source of antibody drug candidates. Retrocyte Display® generates high quality therapeutic antibody drug candidates quickly using a rapid, high-throughput, flow cytometry approach incorporating full-length IgG format human antibody libraries expressed in mammalian B cells (the cell designed by nature for optimal antibody display). This in vitro process is supported by the in vivo HU-PAC® filter, used to select only those antibody product candidates with the most desirable drug characteristics. 4-Antibody provides access to its technologies to select pharmaceutical R&D collaborators and is also generating an in-house pipeline of antibody drugs. The Company’s lead development product is an anti-cytomegalovirus antibody drug. 4-Antibody is a private company with strong, commercially-experienced leadership located in Basel, Switzerland and Jena, Germany. For more information please visit: www.4-antibody.com
Further Information:
Dr Robert Burns
CEO
4-Antibody AG
t: +41 61 697 1351
e: robert.burns@4-antibody.com
Dr Douglas Pretsell
Associate Partner
College Hill
t: +44 20 7866 7868
e: douglas.pretsell@collegehill.com